Penumbraの空売り状況は、投資家がPenumbraの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Penumbra (NYSE:PEN) 株価情報, 空売り情報

Penumbra

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Movers

Trading Ideas

BIMI

DALN

FFIE

FGEN

GRPN

JTAI

LMND

MGNX

NUZE

PITA

PMEC

POWL

TBIO

TIVC

アドバンスト マイクロ デバイセズ社 (NASDAQ:AMD) の株は、予想を上回る第2四半期決算を受けて本日のプレマーケット取引で急騰している。

AMD株価上昇　決算を受けて

Penumbra Inc

Pendle - United States Dollar

Penguin Solutions, Inc. - Ordinary Shares

Penguin Solutions Inc

Peninsula Energy Ltd

PENINSULA ENERGY LTD by Peninsula Energy Ltd.

PENN Entertainment Inc

PENTAMASTER CORP BHD by PENTAMASTER CORP BHD.

PENNANT INTL GRP PLC by Pennant International Group PLC

Penumbra Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is trading higher after the company reported better-than-expected <a href="https://www.benzinga.com/pressreleases/25/02/n43796948/penumbra-inc-reports-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">fourth-quarter earnings</a>.
The medical device company reported:
<ul>
<li>Adjusted EPS of 97 cents, up from 76 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 90 cents</a>.</li>
<li>Sales of $315.52 million, up 10.8% year over year and beating the consensus of $311.55 million.</li>
<li>Global thrombectomy product Q4 sales grew to $220.1 million, an increase of 15.4% in reported and constant currency</li>
<li>U.S. thrombectomy product sales increased by 27.3%.</li>
<li>Global embolization and access product revenues grew to $95.4 million in the fourth quarter of 2024, an increase of 1.6%, or 1.5% in constant currency</li>
<li>U.S. embolization and access product revenue increased by 8.9%.</li>
<li>Operating income reached $42.8 million, with an adjusted&nbsp;operating income of $48.6 million&nbsp;in the fourth quarter of 2024.</li>
<li>Q4 net income reached $33.7 million, and adjusted EBITDA was $63.7 million, with margins of 10.7% and 19.8%, respectively.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42534137/penumbra-is-poised-to-gain-share-in-an-expanding-market-says-bullish-analyst" rel="noreferrer noopener">Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst</a>
<h2 class="wp-block-heading">Penumbra Guidance</h2>
The company forecasts fiscal year 2025 sales of $1.34 billion-$1.36 billion versus a consensus of $1.36 billion.
Penumbra projects the U.S. thrombectomy franchise will grow 19% to 20% year over year, driven primarily by its computer-assisted vacuum thrombectomy products.
The company also expects gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to 13% to 14% of revenue for 2025.
Analyst reactions:
<ul>
<li>Baird maintains the Outperform rating on Penumbra, raising the price target <a href="https://www.benzinga.com/quote/PEN/analyst-ratings" target="_blank" rel="noreferrer noopener">from $305 to $328</a>.</li>
<li>Needham reiterates Penumbra&#8217;s Hold rating.</li>
<li>Morgan Stanley maintains Penumbra with an Equal-Weight, raising the price target from $240 to $260.</li>
<li>Piper Sandler reiterates Penumbra with an Overweight, increasing the price target from $250 to $330.</li>
<li>Wells Fargo also reaffirms Penumbra&#8217;s Overweight rating, with a price target of $305, up from $275.</li>
<li>UBS analyst maintains Penumbra with a Buy and raises the price target from $305 to $320.</li>
<li>Canaccord Genuity maintains the Buy rating on Penumbra and raises the price target from $323 to $340.</li>
<li>Truist Securities reaffirms the Buy rating for Penumbra and raises the price target from $285 to $325.</li>
<li>RBC Capital maintains Penumbra with an Outperform rating and raises the price target from $285 to $313.</li>
<li>JP Morgan maintains Penumbra with an Overweight rating and raises the price target from $230 to $285.</li>
</ul>
Price Action: Penumbra stock is up 11.3% at $301.89 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43815436/supernus-pharmaceuticals-stock-falls-on-disappointing-data-from-treatment-resistant-depression-trial" target="_blank" rel="noreferrer noopener">Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial</a></li>
</ul>
Image: Shutterstock

Earnings

News

Guidance

Health Care

Price Target

Analyst Ratings

General

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

U.S. stocks were lower, with the Dow Jones falling over 200 points on Wednesday.
Shares of Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and FY25 outlook. It also recommended <a href="https://in.benzinga.com/25/02/43812509/garmin-q4-earnings-wearables-and-adventure-watches-drive-growth-raises-dividend-20-projects-68-billion-revenue-for-2025">20% dividend hike</a>.
Garmin reported fiscal fourth-quarter 2024 revenue growth of 23% year-on-year to $1.82 billion, beating the analyst consensus estimate of $1.70 billion. The GPS navigation and wearable technology company's proforma EPS of $2.41 beat the analyst consensus estimate of $2.03.
Garmin shares jumped 14.3% to $245.41 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) shares jumped 61.3% to $49.21.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) gained 26.4% to $21.40 after the company reported better-than-expected fourth-quarter sales results and issued first-quarter revenue guidance with its midpoint above estimates.</li>
<li>Compass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) surged 23.8% to $9.89 after the company reported better-than-expected fourth-quarter revenue results and issued first-quarter revenue guidance above estimates.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) gained 22.6% to $71.75 after the company announced plans to introduce at-home lab testing through its platform. Also, Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $38 to $68.</li>
<li>The Andersons, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANDE#NASDAQ">ANDE</a>) rose 21.1% to $49.38 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Appian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) gained 20.8% to $38.69 after the company reported better-than-expected quarterly EPS and revenue.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 15.5% to $64.47 on possible continued momentum from last week. Investors await an update from the company regarding its delayed filing.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 14.4% to $33.46 after Scotiabank initiated coverage on the stock with a Sector Outperform rating and announced a $102 price target.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 14.4% to $3.8350 after the company announced it received FDA authorization for an expanded access program offering alternative source of BCG for bladder cancer patients.</li>
<li>Penumbra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) rose 13.2% to $306.92 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) gained 8.8% to $37.97 following upbeat quarterly earnings.</li>
<li>RB Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) rose 8.8% to $105.06 following better-than-expected fourth-quarter financial results.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) gained 7.7% to $62.36 after the company announced the introduction of its Mplab AI coding assistant, which leverages the power of AI to assist software developers and engineers in writing and debugging code.</li>
<li>Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) gained 7.3% to $236.22 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) rose 5.8% to $51.70 following upbeat earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43811979/top-3-financial-stocks-that-may-collapse-in-q1">Top 3 Financial Stocks That May Collapse In Q1</a></li>
</ul>

Markets

ANDE

APPN

ATGL

COMP

GRMN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IBRX

MCHP

SEDG

SMCI

VKTX

Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday

JP Morgan analyst Robert Marcus maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $230 to $285.

JP Morgan Maintains Overweight on Penumbra, Raises Price Target to $285

Truist Securities analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $285 to $325.

Truist Securities Maintains Buy on Penumbra, Raises Price Target to $325

RBC Capital analyst Shagun Singh maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $285 to $313.

RBC Capital Maintains Outperform on Penumbra, Raises Price Target to $313

Canaccord Genuity analyst Jason Mills maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $323 to $340.

Canaccord Genuity Maintains Buy on Penumbra, Raises Price Target to $340

UBS analyst Priya Sachdeva maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $305 to $320.

UBS Maintains Buy on Penumbra, Raises Price Target to $320

Wells Fargo analyst Larry Biegelsen maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $275 to $305.

Wells Fargo Maintains Overweight on Penumbra, Raises Price Target to $305

Piper Sandler analyst Matt O'Brien reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $250 to $330.

Reiteration

Piper Sandler Reiterates Overweight on Penumbra, Raises Price Target to $330

WIIM

Penumbra shares are trading higher after Baird and Morgan Stanley raised their respective price targets on the stock.

Morgan Stanley analyst Kallum Titchmarsh maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Equal-Weight and raises the price target from $240 to $260.

Morgan Stanley Maintains Equal-Weight on Penumbra, Raises Price Target to $260

Needham analyst Mike Matson reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) from Hold to Hold.

Needham Reiterates Hold on Penumbrato Hold

Baird analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $305 to $328.

Baird Maintains Outperform on Penumbra, Raises Price Target to $328

Penumbra shares are trading higher after the company reported Q4 earnings and revenue above estimates.

Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) sees FY2025 sales of $1.340 billion-$1.360 billion vs $1.36 billion analyst estimate.

Penumbra Sees FY2025 Sales $1.340B-$1.360B vs $1.36B Est

Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.90 by 7.78 percent. This is a 27.63 percent increase over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $315.52 million which beat the analyst consensus estimate of $311.55 million by 1.27 percent. This is a 10.83 percent increase over sales of $284.68 million the same period last year.

Earnings Beats

Penumbra Q4 Adj $0.97 Beats $0.90 Estimate, Sales $315.52M Beat $311.55M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sohu.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>) is estimated to report earnings for its fourth quarter. 
• Expeditors Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) is projected to report quarterly earnings at $1.44 per share on revenue of $2.81 billion. 
• Franklin Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $465.87 million. 
• Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) is estimated to report quarterly earnings at $3.62 per share on revenue of $1.01 billion. 
• GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $82.24 million. 
• Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) is projected to report quarterly earnings at $2.19 per share on revenue of $1.67 billion. 
• Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $350.45 million. 
• Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) is estimated to report quarterly earnings at $1.75 per share on revenue of $1.81 billion. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $173.40 million. 
• Donnelley Financial Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIN#NYSE">DFIN</a>) is estimated to report quarterly earnings at $0.49 per share on revenue of $169.20 million. 
• Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) is projected to report quarterly loss at $0.99 per share on revenue of $117.83 million. 
• Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $5.71 billion. 
• Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) is likely to report quarterly earnings at $1.97 per share on revenue of $954.17 million. 
• Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $1.37 billion. 
• Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $135.89 million. 
• Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) is likely to report quarterly earnings at $0.77 per share on revenue of $4.42 billion. 
• Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) is expected to report quarterly earnings at $1.75 per share on revenue of $938.91 million. 
• iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $909.96 million. 
• Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $3.17 billion. 
• Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is expected to report quarterly earnings at $1.78 per share on revenue of $4.56 billion. 
• Great Lakes Dredge &amp; Dock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $211.20 million. 
• Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>) is likely to report quarterly earnings at $1.07 per share on revenue of $303.41 million. 
• Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $232.29 million. 
• Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) is expected to report quarterly earnings at $1.29 per share on revenue of $1.22 billion. 
• Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $8.33 billion. 
<h3>Companies Reporting After The Bell</h3>
• James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $960.80 million. 
• RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) is projected to report quarterly earnings at $0.79 per share on revenue of $1.06 billion. 
• Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) is expected to report earnings for its first quarter. 
• Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $71.90 million. 
• ReNew Energy Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $264.79 million. 
• Select Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTTR#NYSE">WTTR</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $338.92 million. 
• Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $85.39 million. 
• TPG RE Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRTX#NYSE">TRTX</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $27.98 million. 
• SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) is likely to report earnings for its fourth quarter. 
• Star Bulk Carriers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $238.48 million. 
• TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) is expected to report quarterly loss at $0.02 per share on revenue of $47.30 million. 
• BlueLinx Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXC#NYSE">BXC</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $700.66 million. 
• Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) is projected to report quarterly loss at $0.03 per share on revenue of $1.29 billion. 
• Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) is projected to report quarterly loss at $0.16 per share on revenue of $114.25 million. 
• Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) is projected to report quarterly loss at $0.05 per share on revenue of $3.14 billion. 
• Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) is expected to report quarterly loss at $0.24 per share on revenue of $781.68 million. 
• Perdoceo Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $160.12 million. 
• Iamgold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) is likely to report earnings for its fourth quarter. 
• La-Z-Boy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $516.47 million. 
• CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) is likely to report earnings for its fourth quarter. 
• CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $1.93 billion. 
• Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) is likely to report quarterly earnings at $1.17 per share on revenue of $286.07 million. 
• Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) is likely to report quarterly earnings at $1.22 per share on revenue of $1.65 billion. 
• CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $701.59 million. 
• Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) is expected to report quarterly earnings at $0.78 per share on revenue of $123.21 million. 
• Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFA#NASDAQ">BELFA</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $128.50 million. 
• Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $15.18 million. 
• Unisys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $550.93 million. 
• Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is expected to report quarterly earnings at $2.05 per share on revenue of $1.91 billion. 
• XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $828.34 million. 
• Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $600.32 million. 
• Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $726.70 million. 
• Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) is estimated to report quarterly earnings at $0.31 per share on revenue of $260.00 million. 
• Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) is estimated to report quarterly earnings at $1.19 per share on revenue of $65.70 million. 
• Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $1.21 billion. 
• Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $12.00 million. 
• Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $2.69 billion. 
• SSR Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSRM#NASDAQ">SSRM</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $244.25 million. 
• BrightSpire Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSP#NYSE">BRSP</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $48.20 million. 
• Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) is likely to report earnings for its fourth quarter. 
• Hackett Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $75.64 million. 
• Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) is projected to report quarterly earnings at $0.57 per share on revenue of $1.90 billion. 
• Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is expected to report quarterly earnings at $0.90 per share on revenue of $311.52 million. 
• JBG SMITH Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBGS#NYSE">JBGS</a>) is projected to report earnings for its fourth quarter. 
• Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $8.31 million. 
• Industrial Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILPT#NASDAQ">ILPT</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $110.30 million. 
• Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) is estimated to report quarterly earnings at $1.84 per share on revenue of $999.09 million. 
• Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is projected to report quarterly earnings at $0.74 per share on revenue of $7.04 billion. 
• Community Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHCT#NYSE">CHCT</a>) is expected to report quarterly earnings at $0.54 per share on revenue of $29.90 million. 
• Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) is estimated to report quarterly earnings at $0.42 per share on revenue of $113.93 million. 
• Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHB#NASDAQ">RUSHB</a>) is expected to report earnings for its fourth quarter. 
• Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHA#NASDAQ">RUSHA</a>) is projected to report quarterly earnings at $0.83 per share on revenue of $1.86 billion. 
• Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) is expected to report quarterly earnings at $1.20 per share on revenue of $997.44 million. 
• Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $315.20 million. 
• Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) is estimated to report quarterly earnings at $1.25 per share on revenue of $2.39 billion. 
• MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $722.85 million. 
• Gladstone Commercial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $38.20 million. 
• EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $1.82 billion. 
• Comstock Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRK#NYSE">CRK</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $378.74 million. 
• Genworth Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNW#NYSE">GNW</a>) is likely to report earnings for its fourth quarter. 
• Innospec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOSP#NASDAQ">IOSP</a>) is estimated to report quarterly earnings at $1.37 per share on revenue of $447.40 million. 
• Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $330.88 million. 
• Sasol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) is expected to report earnings for its fourth quarter. 
• Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) is expected to report earnings for its fourth quarter. 
• Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $4.30 billion. 
• Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is estimated to report quarterly earnings at $1.83 per share on revenue of $1.35 billion. 
• Ternium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) is projected to report quarterly earnings at $1.28 per share on revenue of $4.49 billion. 
• Andersons (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANDE#NASDAQ">ANDE</a>) is likely to report quarterly earnings at $0.94 per share on revenue of $2.73 billion. 
• Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) is likely to report quarterly loss at $0.96 per share on revenue of $1.95 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADEA

ALLE

ANET

AXSM

BELFA

BELFB

BIDU

BLKB

BMBL

BRSP

CDNS

CHCT

CSGP

DFIN

EXPD

FELE

FOUR

GLDD

GOOD

HALO

HCKT

HLMN

ILPT

IOSP

JBGS

LBTYA

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MOBX

MTDR

NGVT

PRDO

QUAD

RUSHA

RUSHB

SAND

SBLK

SEVN

SMLR

SOHU

SPNS

SPNT

SSRM

TCMD

TRTX

TRUE

VTMX

WTTR

Earnings Scheduled For February 18, 2025

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $271.1, a high estimate of $323.00, and a low estimate of $235.00. Surpassing the previous average price target of $230.75, the current average has increased by 17.49%.
<img src="https://www.benzinga.com/files/images/story/2025/1737486036_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Penumbra by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Steve Lichtman</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$323.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$248.00</td>
<td>$244.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Penumbra's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Penumbra analyst ratings.</a>
<h2>About Penumbra</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
<h3>Penumbra: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Penumbra's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.11% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Penumbra's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.81%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Penumbra's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Assess Penumbra: What You Need To Know

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Wood Lay initiated coverage on FirstSun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) with an Outperform rating and announced a price target of $46. Firstsun Capital shares closed at $39.49 on Friday. <a href="https://www.benzinga.com/quote/fsun/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>China Renaissance analyst Colin Liu initiated coverage on MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy rating and announced a price target of $351. MongoDB shares closed at $253.11 on Friday. <a href="https://www.benzinga.com/quote/msb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jason Gursky initiated coverage on Curtiss-Wright Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Buy rating and announced a price target of $410. Curtiss-Wright shares closed at $366.92 on Friday. <a href="https://www.benzinga.com/quote/cw/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Priya Sachdeva initiated coverage on Penumbra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy rating and announced a price target of $305. Penumbra shares closed at $263.69 on Friday. <a href="https://www.benzinga.com/quote/pen/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jason Gursky initiated coverage on V2X, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Buy rating and announced a price target of $64. V2X shares closed at $52.93 on Friday. <a href="https://www.benzinga.com/quote/vvx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MDB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-1024x494.png" alt="" class="wp-image-742334" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-1024x494.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-768x370.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43091705/top-4-health-care-stocks-you-may-want-to-dump-in-q1">Top 4 Health Care Stocks You May Want To Dump In Q1</a></li>
</ul>

Initiation

Pre-Market Outlook

FSUN

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

UBS analyst Priya Sachdeva initiates coverage on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy rating and announces Price Target of $305.

UBS Initiates Coverage On Penumbra with Buy Rating, Announces Price Target of $305

Press Releases

Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024

Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke

Penumbra, Inc. Reports Third Quarter 2024 Financial Results

New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025

Comments

Penumbra

空売り

Penumbra (NYSE:PEN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル